BOSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) — Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that members of the management team will participate in two upcoming virtual investor conferences in February:
A live webcast of the SVB Leerink presentation will be accessible through the investors section of www.akouos.com. To access the webcast, please go to the Akouos website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. An archived replay will be available on Akouos’s website for 30 days following the conference.
About Akouos
Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals living with disabling hearing loss worldwide. Leveraging its precision genetic medicine platform that incorporates a proprietary adeno-associated viral (AAV) vector library and a novel delivery approach, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, Akouos was founded in 2016 by leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy.
Contacts
Media:
Katie Engleman, 1AB
katie@1abmedia.com
Investors:
Courtney Turiano, Stern Investor Relations
Courtney.Turiano@sternir.com
CHICAGO--(BUSINESS WIRE)--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a…
Multi-modality showcase brings hands-on experience to care delivery for a wide range of vascular diseases…
Experienced global CFO adds depth in financial strategy and operating excellence to Smartsheet boardBELLEVUE, Wash.--(BUSINESS…
The Centers for Medicare & Medicaid Services revise the National Coverage Determination of allogeneic hematopoietic…
Feedback provides greater clarity on regulatory requirements for planned Phase 2b trial BOTHELL, Wash. (March…
DUBLIN--(BUSINESS WIRE)--The "Global Medical Device Connectivity Market: Analysis By Product & Services, By Technology, By…